Insulet Co. (NASDAQ:PODD) Shares Sold by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC decreased its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 6.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 75,982 shares of the medical instruments supplier's stock after selling 4,810 shares during the quarter. Stephens Investment Management Group LLC owned about 0.11% of Insulet worth $19,837,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Baillie Gifford & Co. increased its position in Insulet by 20.7% during the third quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier's stock valued at $529,669,000 after acquiring an additional 389,639 shares during the last quarter. Geode Capital Management LLC increased its position in Insulet by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier's stock worth $403,339,000 after buying an additional 22,850 shares in the last quarter. Westfield Capital Management Co. LP increased its position in Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier's stock worth $175,697,000 after buying an additional 163,388 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Insulet by 43.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier's stock worth $148,091,000 after buying an additional 193,839 shares in the last quarter. Finally, Fisher Asset Management LLC increased its position in Insulet by 0.9% in the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier's stock worth $81,719,000 after buying an additional 3,113 shares in the last quarter.

Insulet Stock Up 0.9 %

Shares of NASDAQ:PODD traded up $2.57 on Thursday, reaching $282.12. The company had a trading volume of 635,913 shares, compared to its average volume of 530,356. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46. The firm's 50 day simple moving average is $271.44 and its 200-day simple moving average is $243.41. The firm has a market capitalization of $19.79 billion, a PE ratio of 48.31, a PEG ratio of 3.61 and a beta of 1.23. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PODD shares. Sanford C. Bernstein started coverage on Insulet in a research report on Wednesday, November 6th. They set an "outperform" rating and a $300.00 target price for the company. Morgan Stanley increased their target price on Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a research report on Monday, November 11th. Wells Fargo & Company increased their target price on Insulet from $290.00 to $305.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 11th. Canaccord Genuity Group increased their price target on Insulet from $269.00 to $304.00 and gave the company a "buy" rating in a research note on Monday, December 9th. Finally, Barclays raised their price objective on Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $277.13.

Insider Activity

In other news, EVP Eric Benjamin sold 12,394 shares of the firm's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company's stock, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Lauren Budden sold 915 shares of the firm's stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares of the company's stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.47% of the company's stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.